SV7 Impact Medicine Fund LP is a venture capital fund based in London, United Kingdom. Its most recent Form D, filed Jun 25, 2019, reports no sales yet. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Michael Ross; James Costine; Catherine Bingham.
- Total raised
- $0Cumulative sales reported on Form D
- Investors
- 0
- First sale
- —
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Michael Ross; James Costine; Catherine Bingham
- Latest Form D
- Jun 25, 2019
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about SV7 Impact Medicine Fund LP
What is the minimum investment for SV7 Impact Medicine Fund LP?
SV7 Impact Medicine Fund LP's latest Form D, filed Jun 25, 2019, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in SV7 Impact Medicine Fund LP?
SV7 Impact Medicine Fund LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has SV7 Impact Medicine Fund LP raised?
SV7 Impact Medicine Fund LP's latest Form D, filed Jun 25, 2019, reports no sales yet.
Where is SV7 Impact Medicine Fund LP based?
SV7 Impact Medicine Fund LP is based in London, United Kingdom.
Size compared with every venture capital fund
This fund hasn't reported any sales yet.